von Hippel-Lindau (VHL) disease results from germline and somatic mutations in the VHL tumor suppressor gene and is characterized by highly vascularized tumors. VHL mutations lead to stabilization of hypoxia-inducible factor (HIF), which up-regulates proangiogenic factors such as vascular endothelial growth factor (VEGF). This pathway is therefore believed to underlie the hypervascular phenotypes of the VHL tumors. However, recent studies have identified novel VHL functions that are independent of the HIF-VEGF pathway. In addition, a potential role of VHL in the tumor microenvironment, which carries heterozygous VHL mutations in VHL patients, has been overlooked. Here, we report a novel HIF-independent VHL function in the endothelium. VHL knockdown in primary human microvascular endothelial cells caused defective turnover of surface fibroblast growth factor (FGF) receptor, increased extracellular signal-regulated kinase signaling, and ETS1 activation, leading to increased cell motility in response to FGF and three-dimensional cord formation in vitro. HIF-A knockdown in VHL loss-of-function endothelial cells does not impede their elevated in vitro angiogenic activity. Importantly, the elevated angiogenic response to FGF is recapitulated in Vhl-heterozygous mice. Thus, partial loss of function of VHL in endothelium may be a contributing factor in tumor angiogenesis through a HIF-VEGF-independent mechanism.
Introduction
The von Hippel-Lindau (VHL) disease is a multiple tumor syndrome resulting from inactivation of the VHL tumor suppressor gene on chromosome 3p25 (1) (2) (3) . The disease is characterized by development of highly vascularized benign and malignant tumors, including retinal and central nervous system hemangioblastoma, pheochromocytoma, and clear-cell renal cell carcinoma (RCC). The VHL protein (pVHL) has been shown to function as an E3 ubiquitin ligase (4) (5) (6) . Prominent among its targets are the a subunits of the hypoxia-inducible factor (HIF; refs. 3, 7-9). Because HIF directly activates angiogenic factors, such as vascular endothelial growth factor (VEGF), it is widely accepted that the constitutively activated HIF activity in VHL mutant tumor cells can account for the hypervascular phenotypes in the VHL disease.
However, there is increasing evidence to suggest that pVHL has multiple cellular functions besides being a negative regulator of HIF-a (10) . Among them, loss of VHL function is known to result in dysregulation of cytoskeletal organization and ECM assembly (11) (12) (13) . Some of these defects have been found to correlate with a well-documented VHL mutant phenotype of increased cell motility (12, 14, 15) . In our previous studies, we showed that VHL null RCC-derived cells exhibit elevated motility and that this phenotype is at least in part the result of cell surface accumulation of fibroblast growth factor (FGF) receptor 1 (FGFR1) and enhanced signaling via extracellular signal-regulated kinase 1/2 (ERK1/2) (16) .
It is worth noting that the majority of VHL disease studies have focused on VHL mutations within tumor cells and have often overlooked the fact that all VHL patients are heterozygous mutants for all somatic cells. It is tempting to contemplate the possibility that partial loss of function of VHL in the stroma, including the endothelium, may contribute to the hypervascular phenotype. Indeed, recent evidence supports this notion. For example, conditional Vhl knockout in the endothelial cells resulted in embryonic lethality with vascular defects similar to those in Vhl homozygotes (17) . Also, it has been shown that mice carrying one allele of germline VHL null mutation (i.e., heterozygous mice) developed blood vessel tumors of the liver that are comparable or more severe than vascular tumors resulting from specific homozygous conditional knockout in the hepatocytes (18) . Additional studies have confirmed that VHL heterozygocity can predispose mice to develop severe vascular lesions (19) , although the exact mechanism is unclear. In this report, we show that partial loss of VHL function in matured endothelial cells confers elevated angiogenic activity via up-regulated FGFR signaling.
Materials and Methods
Cell lines and reagents. VHL + primary human microvascular endothelial cells (HMVEC) isolated from neonatal skin were from Cambrex. Cells were maintained in endothelial cell basal medium (Cambrex) supplemented with 5% fetal bovine serum + SingleQuots cytokine and growth factor supplement kit from Cambrex. Cells were used within eight to nine passages and grown in culture dishes coated with bovine type I monomeric collagen solution ( from Inamed Biomaterials). Transfection of HMVECs was performed by electroporation, which consistently achieved f80% transfection efficiency. PD98059 inhibitor and Akt inhibitor V, Triciribine, are from Calbiochem.
RNA interference. Plasmid-based short hairpin RNAs (shRNA) were constructed as follows: target sequences (VHL shRNA-I, gagaactgggacgaggccg; VHL shRNA-II, gctgcccgtatggctcaac; HIF-1a shRNA, aacgacacagaaactgatgac; and control, random sequence) were cloned into pCDNA-based plasmid downstream of U6 promoter. Validated FGFR2 small interfering RNA (siRNA) and control siRNA were obtained from Santa Cruz. Both VHL and HIF-1a specific siRNA targets have been used successfully (16, 20, 21) . AdEts1 siRNA vector and the control virus carrying random oligo sequence are a kind gift from Dr. Maria Trojanowska, Medical University of South Carolina. AdEts1 siRNA target sequence is cagacaccttgcagaatga.
Scratch assay. HMVECs were grown to 90% confluency in collagencoated six-well plates and scratched with a 1,000-AL pipette tip. Fresh complete EBM2 medium was added, and wound-healing was followed for 24 h. Cell proliferation was monitored by staining of cells with rabbit polyclonal Ki-67 proliferation marker (Abcam). Assay was performed in triplicate, and the results were analyzed using Student's t test.
Transwell migration assay. Transwell chamber (Corning; 24-well 8-Am pore size) assays were performed using 2 Â 10 4 cells per insert seeded into the upper chamber in 1% serum and no growth factor supplements. The bottom chamber contained low serum (1%) alone, low serum + basic human recombinant FGF (Promega) + 2.5 Ag/mL heparin (Sigma), or low serum + human recombinant VEGF 165 (BD Biosciences) + 2.5 Ag/mL heparin (Sigma). Migration was followed over 24 h. Inserts were rinsed in 1Â PBS, and cells on the upper side were removed with a cotton swab. Migrated cells attached to bottom side were stained with crystal violet and counted using a 10Â objective focused at the center. Results were analyzed using Student's t test.
Three-dimensional in vitro angiogenesis assay. The assay followed the previously described protocol (22, 23) with modifications. Monolayers of HMVECs (f80% confluency) grown on collagen-coated LabTek chambered slides were overlaid with a 1-mm layer of collagen type I gel followed by a second 3-mm collagen-Matrigel layer (3:1) mixed with indicated numbers of primary human dermal fibroblasts. Growth Factor Reduced BD Matrigel Matrix was obtained from BD Biosciences. Complete EBM-2 medium was then added to the chambers. The medium was refreshed after 48 h, and cord formation was observed using light and fluorescent microscopy after 72 h. Cord formation was quantified using NIH ImageJ software to measure total cord length per field. Assay was performed in triplicate chambers for each condition. Statistical analysis was performed using Student's t test. For mitogen-activated protein kinase kinase (MAP/ERK kinase 1) inhibitor (25 Amol/L) or Akt inhibitor V (10 Amol/L) treatments, the inhibitor was applied to monolayer of serum-starved endothelial cells at the indicated concentration for 2 h before addition of collagen layers. Complete media containing inhibitor was then added to chambers after gel overlay and refreshed every 8 h.
Western blotting and antibodies. Western blotting was according to standard procedures. All antibodies were used at recommended dilutions. Mouse monoclonal antibodies are doubly phosphorylated ERK1/2 (dp-ERK; Sigma), h-actin (Sigma), VHL (Neomarkers and Cell Signaling), HIF-1a (Novus Biologicals), phosphothreonine (Zymed), and phosphoserine (Zymed). Rabbit polyclonal antibodies are FGFR2 (Santa Cruz), ERK1/2 (Sigma), Akt (Cell Signaling), phosphorylated Akt (Cell Signaling), ETS1 (Santa Cruz), epidermal growth factor receptor (EGFR; Sigma), and VEGF receptor 2 (VEGFR2; Calbiochem). Secondary antibodies used were HRPO-conjugated antimouse IgG (Sigma) and antirabbit IgG (Sigma).
Immunohistochemistry. Cells were fixed in PBS + 4% paraformaldehyde for 30 min, quenched with PBS + 20 mmol/L Tris-HCl (pH 7.6), and permeabilized with 0.2% Saponin (Sigma) for 15 min at room temperature. Incubation with respective primary and secondary antibodies was done in PBS + 1% bovine serum albumin (BSA) for 1 h at room temperature. Primary antibodies (p-FGFR and VHL from Cell Signaling and LAMP1 from Developmental Studies Hybridoma Bank, University of Iowa) were used at 1:100 dilution. Secondary antibodies used were antimouse-Alexa 546, antirabbit-Alexa 546, antimouse-Alexa 633, and antirabbit-Alexa 633 at 1:200 dilutions. Confocal images were acquired with Olympus IX70 (Fluoview 300).
Cell surface biotinylation. Cells grown in six-well plates were washed with ice-cold PBS (pH 7.4) and incubated with 0.5 mL/well PBS containing 0.5 mg/mL sulfo-NHS-LC-Biotin (Pierce) for 30 min at 4jC. After washing and free cross-linker quenching in PBS + 50 mmol/L Tris-HCl (pH 7.0), cells were lysed with 300 AL/well of 1% Triton-radioimmunoprecipitation assay buffer (RIPA) containing protease inhibitors (Roche). After protein estimation (Pierce BCA), 1.5 mg extracts were incubated with NeutrAvidin Biotin-Binding Protein (Pierce) overnight at 4jC. After washing in RIPA buffer, samples were eluted by boiling in 1Â SDS sample buffer and blotted with indicated antibodies to detect surface receptor fraction. A portion of total input lysate was reserved for detection of total levels of receptors.
Activated receptor chase. Recombinant human basic FGF (bFGF; 400 ng/mL; Promega) was mixed with 2.5 Ag/mL heparin (Sigma) in serumfree media (with 1% BSA) and added to serum-starved cells (6 h) grown on glass coverslips coated with monomeric collagen. Cells were incubated at 4jC for 2 h to allow ligand-receptor engagement, washed with cold plain EBM-2, and chase initiated in prewarmed plain EBM-2 (37jC) for indicated times. Coverslips were lifted and directly fixed in PBS + 4% formaldehyde and stained using indicated antibodies.
Animals. Vhl knockout mice (129S;ICR-Vhlh tm1Bjg /J) are homozygous lethal as described (24) and were obtained from The Jackson Laboratory. Experiments were performed on 8-wk-old to 11-wk-old animals, using the wild-type animals from the same litter as a control. Genotyping followed the instructions provided by the vendor. Animal housing and all experimental procedures were conducted in accordance with current regulations by Institutional Animal Care and Use Committee of Medical University of South Carolina.
In vivo subcutaneous angiogenesis assay. Heparin (25 Ag/mL; from Sigma) was mixed with bFGF (2.5 Ag/mL) in PBS and incubated on ice for 1 h before the solution was diluted 10Â into the Matrigel matrix (BD Matrigel Growth Factor Reduced; BD Biosciences). Mice (ages 8-11 wk) were anesthetized, and 0.5 mL of Matrigel solution was injected in the subcutaneous tissue of the abdominal wall. The opposite side was used as a control (Matrigel without bFGF and heparin). After a 7-d incubation, mice were anesthetized and infused by intracardiac injection with 0.3 mL of fluorescein-isothiocyanate-dextran (FITC-dextran; from Sigma) at 50 mg/mL. The FITC-dextran was allowed to perfuse through the vascular system for 10 min. After euthanasia, the Matrigel plug was removed and the resulting neovessel formation was analyzed by fluorescence microscopy. The images were quantified using NIH ImageJ. Results were analyzed by Student's t test.
Isolation of mouse kidney endothelial cells. Endothelial cells were isolated from kidney cortex of Vhl +/À mice or the wild-type littermates by immunomagnetic purification with anti-CD-31 loaded immunobeads (Dynal) as previously described (25) (26) (27) . Both cell lines were exposed to three rounds of immunopurification and verification for endothelial markers CD31 and von Willebrand factor (vWF) before experimentation.
Results

VHL knockdown HMVECs exhibit increased cell motility.
The potential endothelial function of pVHL was assessed in primary HMVECs isolated from neonatal skin. As shown in Fig. 1A , expression of VHL shRNA, but not control shRNA (scrambled), resulted in significant reduction in pVHL levels.
''Scratched wound-healing'' and transwell migration assays were used to quantify the migratory properties of VHL + and VHL knockdown HMVECs. In wound-healing experiments, VHL knockdown cells filled f80% of a f500-Am wound within 24 hours, whereas VHL + cells filled only 40% of the wound (Fig. 1A) . Importantly, cell proliferation was found to be similar in VHL + and VHL knockdown HMVECs (stained with Ki-67; data not shown), suggesting that the observed wound healing results are due to differences in migratory abilities of the cells.
Quantitative analysis of three-dimensional chemotactic migration was assessed using transwell migration assays (Fig. 1B) . First, the intrinsic migratory abilities of VHL + and VHL knockdown cells were assessed using low serum media in the upper and bottom chambers. Next, chemotactic migration toward a proangiogenic stimulus was assessed by adding either of the two major angiogenic factors, bFGF or VEGF, in the bottom chamber. Dosage response of VHL knockdown HMVECs was first established over the concentration range used in various published reports (Supplementary Fig. S1 ; refs. 28, 29) . Optimal dosages (400 ng/mL bFGF and 200 ng/mL VEGF) were chosen for the assays shown in Fig. 1B . Compared with VHL + HMVECs, VHL knockdown HMVECs exhibited significantly increased intrinsic, as well as FGF-stimulated, cell migration (P V 0.05). Interestingly, although VEGF could stimulate migration of both VHL + and VHL knockdown cells, there is no statistically significant difference in their responsiveness to VEGF (P = 0.36). Taken together, VHL knockdown in HMVECs leads to increased migratory ability, which is further preferentially induced by bFGF.
VHL knockdown HMVECs exhibit increased angiogenic activity in vitro. We next assessed the angiogenic potential of VHL knockdown HMVECs using an established three-dimensional in vitro angiogenesis assay (22, 23) , as diagrammed in Fig. 1C . In this assay, HMVECs are first cultured in collagen I-coated wells to f80% confluency before a 1-mm layer of collagen I gel was laid over the monolayer. If cultured alone, the HMVECs remain as a monolayer and barely penetrate the collagen gel (data not shown). However, in the presence of supporting cells, such as primary human dermal fibroblasts embedded in another 3-mm gel layer atop the 1-mm acellular layer, HMVECs migrate into the gel and form cord-like structures. We first tested the cord-forming capability of VHL + and VHL knockdown HMVECs under optimal conditions, i.e., in the presence of ''high amount'' (3.75 Â 10 4 cells in 0.6 mL) of fibroblasts (22) . Whereas both VHL + and VHL knockdown HMVECs migrated into the matrix and formed vessellike cords, VHL knockdown HMVECs formed a significantly Figure 1 . Knockdown of VHL increases cell motility in HMVECs. A, left, HMVECs were transfected with vectors expressing control shRNA or VHL shRNA constructs (shVHL ). Cell lysates were Western blotted using VHL antibody or h-actin antibody as a loading control. The apparent molecular weight of the detected pVHL species (f30 kDa) is indicated. Middle, 90% confluent cell monolayers in six-well culture dishes were scratched with a 1,000-AL pipette tip. Wound healing was followed in control and VHL knockdown HMVECs for 24 h. Right, extent of wound healing was quantified in control and VHL knockdown HMVECs by measuring percentage of wound remaining over time using NIH ImageJ software (n = 3). B, quantification of transwell assays for intrinsic (low serum) and chemotactic (+FGF and +VEGF) cell migration over 24 h for control and VHL knockdown HMVECs (n = 5). C, schematic representation of the three-dimensional coculture system. Cord formation by the HMVECs is supported by stromal cells, such as human dermal fibroblasts, and can be observed within 72 h by confocal microscopy usually at a depth of f100 Am from the bottom of the well. D, left, images taken inside collagen gel of control and VHL knockdown HMVECs cocultured with high (3.75 Â 10 4 per chamber) or low (1.5 Â 10 4 per chamber) amount of fibroblasts (FB ). Right, Cord formation by control and VHL knockdown HMVECs cocultured with high (first and second columns ) or low (third and fourth columns ) amount of fibroblasts was quantified using NIH ImageJ software to measure total cord length per field. Assay was performed in triplicate chambers for each condition. Random fields containing cord formation were chosen for quantification from each condition. Statistical analysis was performed using Student's t test (n = 9 for high fibroblast condition, n = 3 for low fibroblast condition). *, P V 0.05; **, P V 0.01.
(f40%) greater amount of cords (Fig. 1D) . For additional experimental support, this assay was repeated using a second VHL shRNA construct and similar results were observed (Supplementary Fig. S2 ).
The ''high amount'' of fibroblasts used above might mask intrinsic differences in HMVEC activity due to the abundant angiogenic factors supplied by the large number of fibroblasts. Therefore, to test if VHL knockdown cells are more responsive to limited angiogenic stimuli, the cord formation assays were performed in the presence of suboptimal amount of fibroblasts (1.5 Â 10 4 cells in 0.6 mL). Under this condition, VHL + HMVECs could no longer penetrate the collagen gel whereas VHL knockdown HMVECs were still able to invade the gel and organize into cords (Fig. 1D) , suggesting that they are more sensitive and responsive to the reduced proangiogenic signals.
Cell surface accumulation of FGFR in VHL knockdown HMVECs. We have previously shown that Drosophila VHL negatively regulates migration of the tracheal tubule cells, a developmental model for mammalian angiogenesis (30) . We have also shown that abnormal accumulation of FGFR on cell surface resulting from defective endocytosis leads to aberrant cell migration in Drosophila trachea and in renal carcinoma cells (16, 31, 32) . Because our results indicated that VHL knockdown HMVECs exhibited an elevated response to bFGF (Fig. 1B) , we examined whether a similar mechanism involving up-regulation of FGFR signaling is responsible for mediating the motility in HMVECs. We indeed observed increased surface accumulation of activated FGFR (tyrosine 653/654-phosphorylated FGFR) in VHL knockdown HMVECs compared with VHL + HMVECs (Fig. 2A) . The result was also verified using a second VHL shRNA construct ( Supplementary  Fig. S3 ).
The differential membrane accumulation of FGFR was confirmed by surface biotinylation assay. As shown in Fig. 2B , while total cellular levels of FGFR2 remain unchanged with or without Figure 2 . Surface accumulation of FGFR in VHL knockdown HMVECs. A, HMVECs transfected with plasmids expressing either control or VHL shRNA (shVHL) were incubated in complete serum with growth factor supplements and processed for immunostaining with anti-p-FGFR antibody. High levels of surface accumulation of p-FGFR (arrows ) are observed in VHL knockdown HMVECs (shVHL ) but not in control cells. B, control and VHL knockdown HMVECs (shVHL) are labeled with membrane-impermeable sulfo-NHS-LC biotin at 4jC. Samples were immunoprecipitated using NeutrAvidin biotin-binding protein and surface receptor levels detected using indicated antibodies. Total receptor levels were detected from total input lysates (1/12 of the amount used in pull-down) using indicated antibodies. C, ligand-stimulated endocytosis of activated FGFR was synchronized and followed over time. Serum-starved cells were incubated with bFGF + heparin at 4jC for 2 h and then chased with ligand-free media at 37jC over a 40-min period. Arrows denote p-FGFR visible at or near the cell surface at 5 min. Arrowheads in control inset (20 min) denote p-FGFR that is internalized into intracellular vesicles. Arrows in VHL knockdown (20 and 40 min) denote p-FGFR appearing in large aggregates at the tips of cellular projections. D, ligand-stimulated endocytosis of activated FGFR was synchronized and followed for 20 min in control HMVECs. Triplicate wells were double-stained for p-FGFR/LAMP1, p-FGFR/VHL, and LAMP1/VHL, as indicated. Top left, p-FGFR (red) and LAMP1 (green ) colocalize in some vesicles (yellow block arrows ), whereas others contain only p-FGFR (arrowheads ). Top right, VHL (green ) and p-FGFR (red) colocalize in some vesicles (yellow block arrows ) but not others (arrowheads ). Bottom, VHL (green ) does not overlap with LAMP1 (red).
Cancer Research
Cancer Res 2008; 68: (12 VHL, knockdown of VHL leads to a 3-fold increase of surface FGFR2. Note that FGFR1 is expressed at very low levels in these cells (data not shown). Interestingly, surface levels of VEGFR2 are unchanged. We also noted that EGFR levels are higher on the surface of VHL + cells compared with VHL knockdown cells. This intriguing phenomenon has been observed in cultured renal carcinoma cells (16) , although its physiologic significance remains unclear.
VHL regulates endocytosis of activated FGF receptors. Defective endocytosis of FGFR can result in surface retention, leading to prolonged signaling and increased cell migration and invasion in both human and Drosophila (16, (31) (32) (33) . To test if this occurs in VHL knockdown HMVECs, ligand-stimulated endocytosis of activated FGFR was synchronized and followed over time. Serum-starved cells were incubated with bFGF + heparin at 4jC for 2 hours and then chased with ligand-free media at 37jC (Fig. 2C) . Five minutes after initiation of chase, activated FGFR (p-FGFR) is visible at or near the cell surface (denoted by arrows) in both VHL + and VHL knockdown cells. By 20 min after initiation of chase, p-FGFR is mostly internalized into intracellular vesicles (denoted by arrowheads) in the VHL + cells. At this time point, many of these p-FGFR-containing vesicles also stain positive for the late endosome/lysosome marker, LAMP1 (Fig. 2D, top left) , consistent with the notion that the internalized FGFR is targeted for degradation. pVHL is seen associated with some but not all of the p-FGFR-containing vesicles (Fig. 2D, top right) , indicating that pVHL is only associated with p-FGFR in part of the endocytic pathway, perhaps only in the early endosomes. Indeed, pVHL is excluded from the LAMP1-containing vesicles (Fig. 2D, bottom) . At 40 min, most of the internalized p-FGFR is degraded in VHL + cells (Fig. 2C) . This time course is consistent with the normal kinetics of endocytic process of activated receptor tyrosine kinases (34) . In contrast, at 20 and 40 min after receptor chase in VHL knockdown cells, p-FGFR is still present on the cell surface (arrows in Fig. 2C,  bottom) , indicating defective internalization of p-FGFR in VHL knockdown HMVECs. Fig. 2C . ERK1/2 activation was measured by the levels of dp-ERK. Total ERK1/2 and h-actin were used as loading controls. C, VHL knockdown HMVECs (shVHL ) were incubated with 25 Amol/L PD98059 (+) or DMSO (À) for 4 h and then treated with bFGF and heparin followed by ligand-free chase as described in Fig. 2C . Lysates were collected at 30 min after chase. ERK1/2 activation is ameliorated by PD98059 as measured by levels of dp-ERK. D, treatment of VHL knockdown HMVECs (shVHL ) with 25 Amol/L PD98059 significantly reduces cord formation in three-dimensional coculture assay in the presence of high amount of fibroblasts. Statistical analysis was performed using Student's t test (n = 4). **, P V 0.01; ***, P V 0.001. (Fig. 3A) . Interestingly, knockdown of FGFR2 in VHL + cells to the same extent as in VHL knockdown cells (f3-fold) does not result in reduced cord formation, indicating that VHL knockdown cells are more reliant on FGFR signaling for their angiogenic activity. Further analysis of downstream signaling pathways revealed that, whereas Akt pathway remains unaffected (Supplementary Fig. S4A ), ERK1/2 activity, measured by the levels of dp-ERK, is increased in VHL knockdown HMVECs. As shown in Fig. 3B , in VHL knockdown HMVECs, ERK1/2 activation is observed 5 min after pulsed bFGF induction. ERK1/2 activation reaches very high level at 20 min and is maintained through at least 60 min. In contrast, in VHL + cells, the initial levels of ERK1/2 activation are much reduced and the kinetics of signal activation is delayed. There is no activation at 5 min and modest activation at 20 to 60 min after receptor activation. Next, we examined the specific role of ERK1/2 activation in promoting cell migration in VHL knockdown HMVECs. A widely used ERK signaling inhibitor PD98059 dramatically reduced ERK1/2 activation levels in FGF-induced VHL knockdown HMVECs (Fig. 3C) . Concomitantly, VHL knockdown cells treated with PD98059 formed significantly fewer cords than VHL knockdown cells treated with DMSO as control (Fig. 3D) , to a level even lower than the wild-type DMSO-treated counterparts. Consistent with the FGFR2 knockdown results (Fig. 3A) , cord formation by VHL + HMVECs was not affected by ERK inhibition (Fig. 3D) , suggesting that alternative angiogenic pathways that are less dependent on ERK signaling may be used in wild-type endothelial cells. These cellular behaviors are similar to those described as ''oncogene addiction, '' in which a cancer cell becomes overreliant on a Figure 4 . Vhl-heterozygous animals show increased neoangiogenic response to bFGF. Vhl +/À mice or the wild-type littermates were injected s.c. with Matrigel with or without embedded bFGF. Seven days after gel implantation, FITC-dextran was infused by intracardiac injection. The gel was dissected 10 min later. Compared with wild-type, bFGF-loaded Matrigel plug in Vhl +/À induces more abundant neovessels with tortuous and chaotic patterns. Arrows point to examples of bulges typically found in bFGF-induced Vhl +/À vessels. Scale bars, 200 Am. Quantification of the area covered by vessels was performed by measuring the fluorescent area of each picture containing vessels using NIH ImageJ software. The angiogenic response to bFGF is more robust in Vhl +/À mice (n = 6) than in the wild-type counterpart (n = 4). Statistical analysis was performed using Student's t test. *, P V 0.05; **, P V 0.01. +/À and the wild-type littermates were assayed in the three-dimensional coculture system as described in Fig. 1 . A, Western analysis of the cell lysates shows a >50% decrease of pVHL level in the Vhl +/À cells compared with the wild type. B, the endothelial cells were preincubated with live dye CM-Dil. Images were taken at f100 to 150 Am from the bottom of the well (Gel) as well as at the bottom. Vhl +/À cells show high levels of cord formation with few remaining at the bottom, whereas wild-type cells mostly remain at the bottom. Scale bars, 200 Am. The angiogenic activity was measured by unit area covered by networks of Vhl +/À (n = 6) and wild-type (n = 6) mouse kidney endothelial cells. Statistical analysis was performed using Student's t test. **, P V 0.01. pathologically overactivated oncogenic pathway (35) . Thus, our results suggest that in VHL knockdown cells, FGFR-ERK signaling becomes the dominant angiogenic signaling pathway.
VHL Gene Function in Endothelial Cell
We have shown that VHL knockdown in HMVECs did not lead to increased Akt activation (Supplementary Fig. S4A ). As expected, treatment with Akt inhibitor V, Triciribine, had no significant effect on cord formation by VHL knockdown HMVECs ( Supplementary  Fig. S4B and C) .
Heterozygosity of VHL in mouse endothelial cells leads to increased angiogenic activity. To directly test our hypothesis that heterozygosity of VHL is a contributing factor in the hypervascularized phenotype in VHL tumors, we performed in vivo angiogenic assays in heterozygous Vhl knockout mice. In this assay, Matrigel embedded with or without bFGF was implanted s.c. in either Vhl +/À or the wild-type littermates. As shown in Fig. 4 , although both Vhl +/À and wild-type mice exhibit low levels of angiogenesis without bFGF induction, Vhl +/À mice show a significantly higher response to bFGF than the wild-type counterparts. It is also noteworthy that the neovessels induced by bFGF in Vhl +/À show tortuous paths and irregular characteristics (e.g., variable diameters with frequent bulges and narrows), typical of tumor-induced vasculature. In contrast, bFGF-induced vessels in the wild-type animals are usually organized with smooth gradation of diameters. We also observed that Vhl +/À and wild-type mice responded equally well to VEGF-induced angiogenesis (data not shown).
To verify that the increased angiogenic response to bFGF is attributable to the endothelium, endothelial cells were isolated from wild-type and Vhl +/À renal cortex. After three rounds of purification using anti-CD31-conjugated magnetic beads, close to 100% of the cells express both CD31 and vWF (data not shown) and the Vhl +/À cells express <50% of the wild-type level of pVHL (Fig. 5A) . These cells were then used in three-dimensional cord formation assay. As shown in Fig. 5B , Vhl +/À endothelial cells exhibit much higher capacity of cord formation than their wildtype counterparts.
ETS1 transcription factor is activated in VHL knockdown HMVECs. The ETS1 transcription factor is activated after ERK1/2 signaling in many cell types and is specifically expressed in endothelial cells undergoing tumor-induced and developmental angiogenesis (36, 37) . Also, the in vivo angiogenic effect of bFGF can be blocked by dominant-negative ETS1 construct (38) . We therefore examined the role of ETS1 in VHL knockdown HMVECs. A direct measurement for ETS1 activity is to determine the phosphorylation levels at threonine (indicative of activation) or serine (indicative of inactivation) residues (39, 40) . Results of a pull-down assay (Fig. 6A) comparing VHL + and VHL knockdown lysates show greatly increased ETS1 threonine phosphorylation in VHL knockdown lysates at steady-state without acute bFGF induction (compare lanes 1 and 3) . No significant changes in ETS1 serine phosphorylation were observed in VHL knockdown and control lysates with or without bFGF. As expected, bFGF induction of control cells resulted in increased ETS1 threonine phosphorylation to a level close to VHL knockdown cell without induction (compare lanes 1, 2, and 3), confirming the link between FGFR signaling and ETS1 activation, and consistent with the high intrinsic cord formation activity of the VHL knockdown cells (Fig. 1D) . Induction with bFGF did not significantly increase the threonine phosphorylation level further in VHL knockdown cells (compare lanes 3 and 4) . However, we consistently observed a decrease in total ETS1 levels in VHL knockdown HMVECs stimulated with bFGF compared with unstimulated VHL knockdown HMVECs (compare lanes 7 and 8). Although the mechanism of ETS1 down-regulation is currently unknown, it nonetheless indicates that a much greater cellular fraction of the total ETS1 is activated in bFGF-stimulated VHL knockdown HMVECs.
Next, we examined the specific role of ETS1 activation in promoting motility in VHL knockdown HMVECs. We used an adenoviral ETS1-specific shRNA construct at 10 multiplicity of infection (MOI) to reduce expression of ETS1 in VHL knockdown and VHL + HMVECs (Fig. 6B, left) . When ETS1 expression was reduced, migration of VHL knockdown HMVECs in transwell migration assay (Fig. 6B, right) and cord formation in threedimensional coculture assay (Fig. 6C) were significantly reduced whereas cord formation by VHL + HMVECs was not affected, again supporting the notion that VHL mutant HMVECs preferentially rely on the FGFR signaling. In contrast, although knockdown of VHL results in an increase in the HIF-1a levels (Fig. 6D, top left) , as expected, knockdown of HIF-1a in these cells did not impair their cord-forming activity (Fig. 6D , bottom left and right). Taken together, the elevated angiogenic activity of VHL knockdown endothelial cells is HIF independent and therefore likely not mediated by autocrine VEGF signaling loop.
Discussion
Our laboratory has previously reported that loss of function of the Drosophila VHL homologue resulted in ectopic migration and branching of Drosophila tracheal cells, a developmental model for angiogenesis, implying a direct role of VHL in mediating vascular cell motility in vivo (30) . Recently, we showed that elevated motility in VHL null renal carcinoma cells is a direct consequence of cell surface accumulation of FGFR1 and enhanced signaling through ERK1/2 (16) . In this report, we show that the FGFRmediated signaling mechanism is conserved in the endothelial cell model. Using primary HMVECs, knockdown of VHL resulted in selective accumulation of FGFR2, leading to elevated angiogenic activity in response to fibroblasts or induced by bFGF through increased ERK1/2 signaling and ETS1 activity. Surface accumulation of FGFR is due to defective internalization of the activated receptor. This phenotype is selective because the effect does not extend to other receptor tyrosine kinases, such as VEGFR and EGFR. As shown in human RCC cells, pVHL selectively regulates FGFR endocytosis by stabilizing the endocytic activity of metastasis suppressor Nm23, which specifically associates with FGFR-containing endosomes but not EGFR-containing endosomes (16) . Although the molecular mechanism involved in FGFR accumulation is likely similar in the previously reported RCC cells and in the endothelial cells reported here, our new findings are significant in at least three aspects.
First, our results with endothelial cells from heterozygous mice show that the VHL function in regulating FGFR signaling is haploid insufficient; that is, partial loss of VHL function (heterozygosity) can result in profound angiogenic phenotype, providing support for the notion that heterozygous VHL individuals may be more prone to hypervascularized tumors. Furthermore, we show that, whereas ERK signaling inhibitor had no effect on normal HMVEC cord formation activity, it greatly reduced that of the VHL knockdown cells to a level even lower than the wild-type untreated counterparts. This suggests that VHL knockdown cells become overreliant on bFGF stimulation for their angiogenic response and may provide a specific target for antiangiogenic intervention. In a broader implication, our findings also imply that spontaneous VHL mutations in the endothelium may contribute to vascular phenotypes in many lesions, including cancer.
Second, by using knockdown and knockout derivatives of normal primary endothelial cells, instead of reexpressing pVHL in cultured cancer cell lines, we are able to clearly define the direct effect of VHL loss of function, without complication from other accumulated oncogenic modifications.
Third, in this report, we identified the transcription factor ETS1 as a major mediator of the elevated angiogenic activity in VHL mutant HMVECs. This should allow future studies to elucidate the specific angiogenic program that underlies the VHL mutant phenotype, using gene expression profiling based on the ETS1 activity.
We believe these findings are highly significant because the stromal compartment should be considered an integral part of the VHL tumorigenesis system. This is best illustrated by hemangioblastoma. Hemangioblastoma, uncontrolled vessel growth occurring in the central nervous system and retinas of VHL patients, is the most common VHL-associated tumor (41, 42) . Interestingly, because loss of heterozygosity of VHL is found only in cells neighboring the overgrown vessels (42) (43) (44) , termed stromal cells, it is generally believed that the endothelium plays only a passive role in the disease, responding to the VEGF overproduced by the VHL À/À cells. However, this tumor is exceedingly rare in non-VHL patient population (45) , suggesting that heterozygosity of the VHL patient endothelial cells may be a contributing factor. Our finding of elevated angiogenic activity in VHL loss-of-function endothelial cells is consistent with the previous report that a different strain of heterozygous Vhl mice developed spontaneous hemangioma-like lesions in the liver, but no other epithelial VHL tumors (18) . Thus, it is likely that VHL mutant tumor cells (e.g., renal carcinoma cells and the stromal population of the hemangioblastoma lesions) do produce higher levels of angiogenic factors, such as VEGF, but partial loss of VHL in the endothelium also predisposes the tumor microenvironment to hypervascularization via elevated response to FGF that is secreted by the tumor cells or other stromal cells, such as fibroblasts. In light of the modest success using VEGF pathway antagonists in treating VHL Figure 6 . ETS1 transcription factor mediates angiogenic activity of VHL knockdown HMVECs. A, control or VHL knockdown (shVHL ) lysates (1 mg) stimulated with (lanes 2 and 4 ) or without (lanes 1 and 3) bFGF + heparin are incubated with ETS1 antibody and pull-down performed with protein G-sepharose beads. Pulled-down fractions are probed with phosphothreonine (p-Thr ) and reprobed with phosphoserine (p-Ser) antibodies. Total lysates (100 Ag) from control or VHL knockdown HMVECs stimulated with (lanes 6 and 8) or without (lanes 5 and 7) bFGF are probed with ETS1 antibody and reprobed with h-actin for loading control. B, left, treatment of VHL knockdown HMVECs (shVHL ) with 10 MOI of ETS1-specific adeno shRNA (+) reduces ETS1 expression compared with treatment with control (À) virus. Right, transwell migration assay for VHL knockdown HMVECs treated with 10 MOI of control virus (shVHL + control ) or 10 MOI of ETS1-specific adeno siRNA (shVHL + shETS1 ). Statistical analysis was performed using Student's t test (n = 4). C, knockdown of ETS1 expression by 10 MOI ETS1-specific adeno siRNA significantly reduces cord formation by VHL knockdown HMVECs but has no effect on control cells. D, top left, HIF-1a expression in VHL wild-type (control shRNA), VHL single knockdown, and VHL-HIF-1a double knockdown cells. Bottom left, cord formation assay comparing VHL single knockdown (shVHL + control ) and VHL-HIF-1a double knockdown (shVHL + shHIF-1a ). Right, quantification of cord formation assay shown on the left. Statistical analysis was performed using Student's t test (n = 4). *, P V 0.05; ***, P V 0.001.
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Cancer (46) (47) (48) , future improvements to the antiangiogenic therapy against VHL tumors should consider addition of specific FGF signaling antagonists or broader receptor tyrosine kinase blockers.
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